Use of Prolactin Inhibition in the Treatment of Peripartum Cardiomyopathy - Revista Brasileira de Ginecologia e Obstetrícia
I certainly agree with Dr. Melo and colleagues that newer treatments are necessary for the therapy of peripartum cardiomyopathy (PPCM); and particularly in those areas of the world with higher mortality and morbidity rates.
My hope is to encourage Dr. Melo and colleagues, or others, to carry out a carefully controlled study of either cabergoline or bromocriptine in a large group of subjects with PPCM receiving evidence-based standard heart failure treatment alone compared with another group receiving that treatment plus the prolactin-inhibition. This kind of carefully controlled study, in which participants are randomly assigned to different groups, is still waiting to happen.
[…]
Search
Search in:
Search
Search in:
I certainly agree with Dr. Melo and colleagues that newer treatments are necessary for the therapy of peripartum cardiomyopathy (PPCM); and particularly in those areas of the world with higher mortality and morbidity rates.
My hope is to encourage Dr. Melo and colleagues, or others, to carry out a carefully controlled study of either cabergoline or bromocriptine in a large group of subjects with PPCM receiving evidence-based standard heart failure treatment alone compared with another group receiving that treatment plus the prolactin-inhibition. This kind of carefully controlled study, in which participants are randomly assigned to different groups, is still waiting to happen.
[...]
Comments